Neurodegeneration upstart Denali outlines $100M IPO for its growing clinical work
Can a team of neurodegeneration specialists and at least one early-stage drug asset out of Roche’s world-famous Genentech group succeed where so many have failed before it?
I don’t know, but Denali Therapeutics is in the process of trying to raise roughly $100 million through an IPO to find out — which is just a fraction of the $350 million it gathered from some A list investors in its venture megarounds.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.